Sichuan Biokin Pharmaceutical Co., Ltd. Class ASSE: 688506

Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

· Issued by Sichuan Biokin Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-the-completion-of-the-first-subject-enrollment-in-the-phase-iii-clinical-trial-of-bl-m05d1-for-injection-adc-for-previously-first-line-treated-claudin182-positive-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma

Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in the Phase III Clinical Trial of BL-M05D1 for Injection (ADC) for Previously First-Line Treated Claudin18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Company analysis